百济神州新型BCL2抑制剂Sonrotoclax获全球首个批准
The first-in-world approval of Sonrotoclax is a landmark event for BeiGene and a significant development for cancer patients globally, particularly in APAC where B-cell malignancies are prevalent.
Sonrotoclax received its first-in-world regulatory approval for R/R MCL.
百济神州的新型BCL2抑制剂Sonrotoclax已获得其全球首个批准，用于治疗复发/难治性套细胞淋巴瘤（MCL）。这一监管里程碑标志着B细胞恶性肿瘤治疗的重大进展，为选择有限的患者提供了新的治疗选择。该批准基于强有力的临床试验数据，证明了其疗效和安全性。
The first-in-world approval of Sonrotoclax is a landmark event for BeiGene and a significant development for cancer patients globally, particularly in APAC where B-cell malignancies are prevalent. This approval validates BeiGene's R&D capabilities and its commitment to bringing innovative therapies to market. It offers a new hope for patients with limited treatment options and strengthens BeiGene's position in the oncology landscape.
This approval is highly relevant to APAC as it provides a novel treatment option for patients with B-cell malignancies in the region. BeiGene's strong presence in APAC means this drug will likely be a key focus for market access and patient support programs, addressing a critical unmet medical need in countries like China and others across Asia.
此信号在行业全局中的位置。
https://www.beigene.com/press-releases/sonrotoclax-receives-first-in-world-approval-in-relapsed-refractory-mantle-cell-lymphoma
阅读完整来源精选情报直达收件箱。无垃圾邮件，随时退订。
登录后可保存信号笔记。
登录